Vir Biotechnology Enters Multi — Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO — XTEN® Dual — masked T — cell Engagers for Solid Tumors
For best results when printing this announcement, please click on link below: Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN(®) Dual-masked T-cell Engagers for Solid Tumors - Collaboration combines Vir Biotechnology’s T-cell engager